Mitochondrial dysfunction itself can be categorized into two types: the first type represents a mutation of a gene which is associated with the ATP-generating pathway, while the second one is related to various abnormalities such as genetic, biochemic or metabolic, that may weaken the ability of the mitochondria to produce ATP (Haas et al., 2007)
The risk is not danger but diminished effectiveness
Gastrointestinal adverse events were more frequent with tirzepatide (42.5% vs 35.9%), including nausea (25.1% vs 22.4%), vomiting (11.6% vs 9.7%), and diarrhea (24.8% vs 19.1%)
If your kidney function worsens during tirzepatide treatment, your prescriber may pause dose escalation or reduce your current dose
Common causes include water retention (especially after dose increases or during hormonal fluctuations), muscle gain offsetting fat loss (particularly in people who are exercising consistently), metabolic adaptation, and changes in dietary habits that may have gradually increased caloric intake